Nonmotor complications in Parkinson's disease

Movement Disorders

Volumn 20, Issue SUPPL. 11, 2005, Pages

  Adler, Charles H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autonomic dysfunction; Dementia; Motor complications; Non motor complications; Parkinson's disease; Psychosis; Sleep disorders

Indexed keywords

ACETYLCHOLINE; AMANTADINE; ANTIPARKINSON AGENT; APOLIPOPROTEIN E4; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; DONEPEZIL; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; ENTACAPONE; FLUDROCORTISONE; GALANTAMINE; GLYCOPYRRONIUM BROMIDE; LACTULOSE; LAXATIVE; LEVODOPA; MELATONIN; METHYLPHENIDATE; MIDODRINE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; PAPAVERINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SCOPOLAMINE; SEDATIVE AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; TAMSULOSIN; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

ADJUVANT THERAPY; ANXIETY DISORDER; ARTICLE; AUTONOMIC DYSFUNCTION; BLADDER DYSFUNCTION; BLOOD DYSCRASIA; BRADYKINESIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA; DEPRESSION; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FLUID THERAPY; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; INSOMNIA; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MUSCLE RIGIDITY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; RISK FACTOR; SEDATION; SENSITIVITY ANALYSIS; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; TREMOR;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COGNITION DISORDERS; DEMENTIA; GASTROINTESTINAL DISEASES; HUMANS; HYPERHIDROSIS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RESTLESS LEGS SYNDROME; SENSATION DISORDERS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP DISORDERS; URINARY BLADDER DISEASES;

EID: 20544468414     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20460     Document Type: Article

References (65)

1. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
2. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
3. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003; 18:467-486.
4. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:852-856.
5. Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
6. Emre M. Dementia associated with Parkinson's disease. Lancet 2003;2:229-237.
7. Marder K, Jacobs DM. Dementia. In: Factor SA, Weiner WJ, editors. Parkinson's disease: diagnosis and clinical management. New York: Demos Medical Publishing, Inc; 2002. p 125-135.
8. Peran P, Rascol O, Demonet JF, et al. Deficit of verb generation in nondemented patients with Parkinson's disease. Mov Disord 2003; 18:150-156.
9. Hughes TA, Ross HF, Mosa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
10. Louis E, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson's disease. Arch Neurol 1998;54:260-264.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991;48:725-728.
13. Tang-Wai DF, Knopman DS, Geda YE, et al. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 2003;60:1777-1781.
14. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-1228.
15. Uekermann J, Daum I, Peters S, Wiebel B, Przuntek H, Muller T. Depressed mood and executive dysfunction in early Parkinson's disease. Acta Neurol Scand 2003;107:341-348.
16. Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001;108:1319-1325.
17. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.
18. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
19. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-814.
20. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
21. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
22. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
23. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60: 1756-1761.
24. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
25. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl. 5):S1-S88.
26. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-211.
27. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
28. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003;18:510-514.
29. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139.
30. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002; 23(Suppl. 2):S89-S90.
31. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002;17:445-454.
32. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Curr Psychiatr Rep 2002;4:69-73.
33. Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001;6:350-352.
34. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48:1070-1077.
35. Friedman J, Gordon N. Electroconvulsive therapy in Parkinson's disease: a report on five cases. Convuls Ther 1992;8:204-210.
36. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatr Clin Neurosci 1998;10:187-193.
37. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59: 408-413.
38. Hiner BC. Autonomic complications of Parkinson's disease. In: Adler CH, Ahlskog JE, editors. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa: Humana Press; 2000. p 161-174.
39. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:268-272.
40. Bonuccelli U, Lucetti C, Del Dotto P, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 2003;60:1400-1404.
41. Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18:1459-1463.
42. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989;12:375-383.
43. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery in Parkinson disease. Neuropsychiatr Neuropsychol Behav Neurol 2002;15:247-251.
44. Comella CL. Sleep and Parkinson's disease. In: Adler CH, Ahlskog JE, editors. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa: Humana Press; 2000. p 151-160.
45. Comella CL. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep 2003;3:173-180.
46. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58:1019-1024.
47. Maria B, Sophia S, Michalis M, et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med 2003;97: 1151-1157.
48. Young A, Home M, Churchward T, Freezer N, Holmes P, Ho M. Comparison of sleep disturbance in mild versus severe Parkinson's disease. Sleep 2002;25:573-577.
49. Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
50. Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 2003;4:275-280.
51. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.
52. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
53. Shochat T, Loredo J, Ancoli-Israel S. Sleep disorders in the elderly. Curr Treat Options Neurol 2001;3:19-36.
54. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.
55. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002;25:111-114.
56. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002;59:421-424.
57. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003;18: 181-185.
58. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
59. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
60. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-45.
61. Matheson JK, Saper CB. REM sleep behavior disorder: a dopaminergic deficiency disorder? Neurology 2003;61:1328-1329.
62. Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998;51:363-370.
63. Gagnon J, Bedard M, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
64. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
65. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 2003;61: 1418-1420.